PT741577E - Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado - Google Patents

Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado

Info

Publication number
PT741577E
PT741577E PT95910629T PT95910629T PT741577E PT 741577 E PT741577 E PT 741577E PT 95910629 T PT95910629 T PT 95910629T PT 95910629 T PT95910629 T PT 95910629T PT 741577 E PT741577 E PT 741577E
Authority
PT
Portugal
Prior art keywords
alpha
ifn
pct
treating
subtype
Prior art date
Application number
PT95910629T
Other languages
English (en)
Inventor
Graham Russell Foster
Howard Christopher Thomas
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404379A external-priority patent/GB9404379D0/en
Priority claimed from GB9420340A external-priority patent/GB9420340D0/en
Application filed by Imperial College filed Critical Imperial College
Publication of PT741577E publication Critical patent/PT741577E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
PT95910629T 1994-03-07 1995-03-07 Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado PT741577E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404379A GB9404379D0 (en) 1994-03-07 1994-03-07 Therapeutic improvement
GB9420340A GB9420340D0 (en) 1994-10-10 1994-10-10 Therapeutic improvement

Publications (1)

Publication Number Publication Date
PT741577E true PT741577E (pt) 2003-03-31

Family

ID=26304449

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95910629T PT741577E (pt) 1994-03-07 1995-03-07 Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado

Country Status (10)

Country Link
US (1) US6007805A (pt)
EP (1) EP0741577B1 (pt)
JP (1) JP4001379B2 (pt)
AT (1) ATE227133T1 (pt)
AU (1) AU1854695A (pt)
DE (1) DE69528751T2 (pt)
DK (1) DK0741577T3 (pt)
ES (1) ES2186714T3 (pt)
PT (1) PT741577E (pt)
WO (1) WO1995024212A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
IT1295657B1 (it) * 1997-11-04 1999-05-24 Alfa Wassermann Spa Oligopeptidi antiparalleli e oligopeptidi idrofobicamente complementari, matrici che li contengono e loro uso nella
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
GB9818445D0 (en) * 1998-08-24 1998-10-21 Imp College Innovations Ltd Medicaments
CN100420482C (zh) * 2000-11-03 2008-09-24 精达制药公司 ω干扰素在制备用于治疗丙型肝炎的药物中的用途
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4866612B2 (ja) * 2003-11-12 2012-02-01 株式会社林原生物化学研究所 生理活性複合体
CN102344491B (zh) * 2003-12-10 2015-03-11 梅达雷克斯有限责任公司 干扰素α抗体及其用途
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
TW200611910A (en) 2004-05-19 2006-04-16 Maxygen Inc Interferon-alpha polypeptides and conjugates
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1888633A4 (en) 2005-05-18 2010-01-27 Maxygen Inc UNFOLDED INTERFERON ALPHA POLYPEPTIDE
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JPWO2009116491A1 (ja) 2008-03-21 2011-07-21 株式会社林原生物化学研究所 ヒトインターフェロンαサブタイプα８及びその変異蛋白質を特異的に認識するモノクローナル抗体
ES2650667T3 (es) 2009-09-28 2018-01-19 Intarcia Therapeutics, Inc Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB201215873D0 (en) * 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
CA2998456A1 (en) 2015-09-15 2017-03-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
GB8303165D0 (en) * 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPH02197539A (ja) * 1989-01-26 1990-08-06 Tanaka Kikinzoku Kogyo Kk 装飾品用Ｃｏ含有貴金属材料
EP0625991B1 (en) * 1992-02-10 1999-04-28 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Also Published As

Publication number Publication date
EP0741577B1 (en) 2002-11-06
ATE227133T1 (de) 2002-11-15
DK0741577T3 (da) 2003-02-17
AU1854695A (en) 1995-09-25
EP0741577A1 (en) 1996-11-13
US6007805A (en) 1999-12-28
JPH09509955A (ja) 1997-10-07
DE69528751D1 (de) 2002-12-12
DE69528751T2 (de) 2003-07-10
ES2186714T3 (es) 2003-05-16
JP4001379B2 (ja) 2007-10-31
WO1995024212A1 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
PT741577E (pt) Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ES8700053A1 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
BR9810745A (pt) Derivados de benzimidazol
MY130035A (en) Antiviral compounds
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
MY105855A (en) Therapeutic nucleotides.
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
FR2572286B1 (fr) Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
HK1012238A1 (en) Use of benzimidazole anthelmintic in the treatment of microsporidial infections
ES2103811T3 (es) Terapia antiviral.
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
MY104976A (en) Antiviral compounds
MX9307639A (es) Metodo para tratar infecciones virales con terapia conjuntiva con compuestos similares al aciclovir y un analogo de nucleosido 2'-viril substituido.
EP0459176A3 (en) Oligophosphates with antiviral activity
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
MY101495A (en) Treatment of diseases caused by viruses